María González Cao

María González Cao
FACULTATIVO ESPECIALISTA ONCOLOGÍA MÉDICA
Oncología Médicaes/especialidades/oncologia-medica
Ver más especialistas en
Barcelonabarcelona
es/cuadro-medico/oncologo
Datos destacados
- Última publicación:A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1.
Datos del profesional
Hospital Universitari Dexeus
FACULT. ESP. ONCOLOGÍA MÉDICA
Enero 2023 -
Actualidad
Hospital Santa Maria
Facultativo/a esp.
Enero 2006 - Enero 2007
Clínica Universidad de Navarra
Facultativo/a esp.
Enero 2004 - Enero 2006
Hospital Clínic Barcelona
Facultativo/a esp.
Enero 2002 - Enero 2003
Estudio
Licenciada en Medicina y Cirugía
universidad, Universidad de Navarra
Doctorado
Universidad de Navarra
2006
Formación Sanitaria Especializada
Oncología Médica
universidad
A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1.
Journal Article
Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV).
Practice Guideline
COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study.
Journal Article, Research Support, Non-U.S. Govt
Lung cancer patients with COVID-19 in Spain: GRAVID study.
Journal Article, Observational Study
Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer.
Journal Article
Neoantigen personalized vaccine plus anti-PD-1 antibody in cancer patients.
Editorial, Comment
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).
Journal Article
SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry.
Journal Article
SEOM clinical guideline for the management of cutaneous melanoma (2020).
Journal Article
Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma.
Journal Article
Hospital Universitari Dexeus - Grupo Quirónsalud
Calle Sabino Arana, 5-19 - Planta 1
08028 Barcelona Barcelona
© 2025 Quirónsalud - Todos los derechos reservados
























